← brief for 2026-08-12 · Slowing decline

SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials.

Article No results yet Peer reviewed

Key takeaways

This review lays out the case for testing SGLT2 medicines in polycystic kidney disease, an inherited disease that fills the kidneys with cysts. It points out what is still unknown and lists trials now underway. It is a review, so there are no new results yet.

Who did this work

Spatola L · Maccarrone R · Oddo G · Granata S · Zeiler M · Granata A

Source

Article · PubMed, the drug frontier · 2026 Aug 12
https://pubmed.ncbi.nlm.nih.gov/42584781/